GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » Market Cap

Plus Therapeutics (Plus Therapeutics) Market Cap : $7.36 Mil (As of Apr. 27, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Plus Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Plus Therapeutics's share price for the quarter that ended in Dec. 2023 was $1.7501. Plus Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 4.44 Mil. Therefore, Plus Therapeutics's market cap for the quarter that ended in Dec. 2023 was $7.78 Mil.

Plus Therapeutics's quarterly market cap increased from Jun. 2023 ($5.82 Mil) to Sep. 2023 ($6.06 Mil) and increased from Sep. 2023 ($6.06 Mil) to Dec. 2023 ($7.78 Mil).

Plus Therapeutics's annual market cap declined from Dec. 2021 ($16.29 Mil) to Dec. 2022 ($10.65 Mil) and declined from Dec. 2022 ($10.65 Mil) to Dec. 2023 ($7.78 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Plus Therapeutics's Enterprise Value for Today is $2.99 Mil.


Plus Therapeutics Market Cap Historical Data

The historical data trend for Plus Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plus Therapeutics Market Cap Chart

Plus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.31 13.63 16.29 10.65 7.78

Plus Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.65 10.48 5.82 6.06 7.78

Competitive Comparison of Plus Therapeutics's Market Cap

For the Biotechnology subindustry, Plus Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Plus Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's Market Cap falls into.



Plus Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Plus Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$1.7501*4.4441
=$7.78

Plus Therapeutics's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$1.7501*4.4441
=$7.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Plus Therapeutics  (NAS:PSTV) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Plus Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Plus Therapeutics (Plus Therapeutics) Business Description

Traded in Other Exchanges
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.
Executives
Marc H Hedrick officer: President C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Robert P Lenk director LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060
Howard Clowes director 217 DWIGHT ROAD, BURLINGAME CA 94010
Greg Petersen director 3100 MAIN STREET, SUITE 900, HOUSTON TX 77002
Sims Andrew John Hugh Macintyre officer: Chief Financial Officer 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756
Norman D. Lafrance officer: CHIEF MEDICAL OFFICER MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142
Es-johansson An Van director 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
Ag Postfinance 10 percent owner MINGERSTRASSE 20, BERN V8 3030
Bank Sa Swissquote 10 percent owner CHEMIN DE LA CRETAUX 33, GLAND V8 1196
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Ron Martell director PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Mark Marino officer: Chief Medical Officer C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
John David Harris officer: VP and GM of Cell Therapy 3020 CALLAN ROAD, SAN DIEGO CA 92121
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Rickey director